378 A first-in-human (FIH) safety and pharmacological study of SAR405838, a novel HDM2 antagonist, in patients with solid malignancies

Authors :: Sandrine Macé
M. Merqui-Roelvink
A. Le Cesne
J.H.M. Schellens
Garry Schwartz
Mark A. Dickson
Gilles Tuffal
Andrea Varga
Martijn P. Lolkema
George D. Demetri
H. Miao
M.J.A. de Jonge
Wei Zheng
Anthony D. Wagner
V. de Weger
William D. Tap
Source :: European Journal of Cancer. 50:121-122
Publication Year :: 2014
Publisher :: Elsevier BV, 2014.

Subjects :: Cancer Research
Oncology
business.industry
Antagonist
Medicine
In patient
First in human
Pharmacology
business

Full Text Access

Tools